Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
26
07
2023
accepted:
26
03
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
The Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens
Identifiants
pubmed: 38658754
doi: 10.1038/s41586-024-07350-y
pii: 10.1038/s41586-024-07350-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 22460905
pmcid: 3320027
doi: 10.1038/nature11003
McDonald, E. R. 3rd et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592 (2017).
pubmed: 28753431
doi: 10.1016/j.cell.2017.07.005
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511–516 (2019).
pubmed: 30971826
doi: 10.1038/s41586-019-1103-9
Lieb, S. et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. eLife 8, e43333 (2019).
pubmed: 30910006
pmcid: 6435321
doi: 10.7554/eLife.43333
Kategaya, L., Perumal, S. K., Hager, J. H. & Belmont, L. D. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. iScience 13, 488–497 (2019).
pubmed: 30898619
pmcid: 6441948
doi: 10.1016/j.isci.2019.02.006
Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551–556 (2019).
pubmed: 30971823
pmcid: 6580861
doi: 10.1038/s41586-019-1102-x
Kang, S. et al. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine 97, e0019 (2018).
pubmed: 29489646
pmcid: 5851768
doi: 10.1097/MD.0000000000010019
Wang, Q. X. et al. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers. Exp. Hematol. Oncol. 10, 2 (2021).
pubmed: 33397433
pmcid: 7784284
doi: 10.1186/s40164-020-00193-z
Lizardo, D. Y. et al. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim. Biophys. Acta Rev. Cancer 1874, 188447 (2020).
pubmed: 33035640
pmcid: 7886024
doi: 10.1016/j.bbcan.2020.188447
Corcoran, R. B. & Grothey, A. Efficacy of immunotherapy in microsatellite-stable or mismatch repair proficient colorectal cancer-fact or fiction? JAMA Oncol. 6, 823–824 (2020).
pubmed: 32379270
doi: 10.1001/jamaoncol.2020.0504
Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247–257 (2003).
pubmed: 12867608
pmcid: 3584639
doi: 10.1056/NEJMoa022289
Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11–19 (2020).
pubmed: 31725351
doi: 10.1200/JCO.19.02107
Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).
pubmed: 28734759
pmcid: 6207072
doi: 10.1016/S1470-2045(17)30422-9
Fucà, G. et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J. Immunother. Cancer 10, e004001 (2022).
pubmed: 35110358
pmcid: 8811606
doi: 10.1136/jitc-2021-004001
Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812–816 (1993).
pubmed: 8484121
doi: 10.1126/science.8484121
Bonneville, R. et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. 2017, PO.17.00073 (2017).
pubmed: 29850653
Kim, T. M., Laird, P. W. & Park, P. J. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 155, 858–868 (2013).
pubmed: 24209623
doi: 10.1016/j.cell.2013.10.015
van Wietmarschen, N. et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature 586, 292–298 (2020).
pubmed: 32999459
pmcid: 8916167
doi: 10.1038/s41586-020-2769-8
Bohr, V. A. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem. Sci. 33, 609–620 (2008).
pubmed: 18926708
pmcid: 2606042
doi: 10.1016/j.tibs.2008.09.003
Singh, D. K., Ahn, B. & Bohr, V. A. Roles of RECQ helicases in recombination based DNA repair, genomic stability and aging. Biogerontology 10, 235–252 (2009).
pubmed: 19083132
doi: 10.1007/s10522-008-9205-z
Bachrati, C. Z. & Hickson, I. D. RecQ helicases: guardian angels of the DNA replication fork. Chromosoma 117, 219–233 (2008).
pubmed: 18188578
doi: 10.1007/s00412-007-0142-4
Rossi, M. L., Ghosh, A. K. & Bohr, V. A. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair 9, 331–344 (2010).
pubmed: 20075015
pmcid: 2827637
doi: 10.1016/j.dnarep.2009.12.011
Aggarwal, M., Sommers, J. A., Shoemaker, R. H. & Brosh Jr, R. M. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl Acad. Sci. USA 108, 1525–1530 (2011).
pubmed: 21220316
pmcid: 3029756
doi: 10.1073/pnas.1006423108
Aggarwal, M. et al. Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional Fanconi anemia pathway. Cancer Res. 73, 5497–5507 (2013).
pubmed: 23867477
pmcid: 3766423
doi: 10.1158/0008-5472.CAN-12-2975
Parker, M. J. et al. Identification of 2-sulfonyl/sulfonamide pyrimidines as covalent inhibitors of WRN using a multiplexed high-throughput screening assay. Biochemistry 62, 2147–2160 (2023).
pubmed: 37403936
doi: 10.1021/acs.biochem.2c00599
Möbitz, H. Design principles for balancing lipophilicity and permeability in beyond rule of 5 space. ChemMedChem 19, e202300395 (2024).
Su, F. et al. Replication stress induced site-specific phosphorylation targets WRN to the ubiquitin-proteasome pathway. Oncotarget 7, 46–65 (2016).
pubmed: 26695548
doi: 10.18632/oncotarget.6659
Shamanna, R. A. et al. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget 7, 13269–13284 (2016).
pubmed: 26959889
pmcid: 4924640
doi: 10.18632/oncotarget.7906
Zong, D. et al. Comprehensive mapping of cell fates in microsatellite unstable cancer cells support dual targeting of WRN and ATR. Preprint at bioRxiv https://doi.org/10.1101/2023.07.28.550976 (2023).
Zannini, L., Delia, D. & Buscemi, G. CHK2 kinase in the DNA damage response and beyond. J. Mol. Cell. Biol. 6, 442–457 (2014).
pubmed: 25404613
pmcid: 4296918
doi: 10.1093/jmcb/mju045
Hao, S. et al. Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer. Proc. Natl Acad. Sci. USA 119, e2211775119 (2022).
pubmed: 36508676
pmcid: 9907101
doi: 10.1073/pnas.2211775119
Nowsheen, S. & Yang, E. S. The intersection between DNA damage response and cell death pathways. Exp. Oncol. 34, 243–254 (2012).
pubmed: 23070009
pmcid: 3754840
Fujita, K., Kubota, Y., Ishida, H. & Sasaki, Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J. Gastroenterol. 21, 12234–12248 (2015).
pubmed: 26604633
pmcid: 4649109
doi: 10.3748/wjg.v21.i43.12234
Golding, S. E. et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8, 2894–2902 (2009).
pubmed: 19808981
pmcid: 2761990
doi: 10.1158/1535-7163.MCT-09-0519
Derewenda, Z. S. & Vekilov, P. G. Entropy and surface engineering in protein crystallization. Acta Crystallogr. D 62, 116–124 (2006).
pubmed: 16369101
doi: 10.1107/S0907444905035237
Kabsch, W. XDS. Acta Crystallogr. D 66, 125–132 (2010).
pubmed: 20124692
pmcid: 2815665
doi: 10.1107/S0907444909047337
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293–302 (2011).
pubmed: 21460447
pmcid: 3069744
doi: 10.1107/S0907444911007773
Tickle, I. et al. Staraniso (Global Phasing, 2018).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840
pmcid: 2483472
doi: 10.1107/S0021889807021206
Swan, M. K. et al. Structure of human Bloom’s syndrome helicase in complex with ADP and duplex DNA. Acta Crystallogr. D 70, 1465–1475 (2014).
pubmed: 24816114
doi: 10.1107/S139900471400501X
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
pubmed: 15572765
doi: 10.1107/S0907444904019158
Bricogne, G. et al. BUSTER version 2.10. 0 (Global Phasing, 2011).
Wasilko, D. J. et al. The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus. Protein Expr. Purif. 65, 122–132 (2009).
pubmed: 19174191
doi: 10.1016/j.pep.2009.01.002
Zegzouti, H., Zdanovskaia, M., Hsiao, K. & Goueli, S. A. ADP-Glo: a Bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev. Technol. 7, 560–572 (2009).
pubmed: 20105026
doi: 10.1089/adt.2009.0222
Brosh, R. M. Jr, Waheed, J. & Sommers, J. A. Biochemical characterization of the DNA substrate specificity of Werner syndrome helicase. J. Biol. Chem. 277, 23236–23245 (2002).
pubmed: 11956187
doi: 10.1074/jbc.M111446200
Gubler, H. et al. Helios: history and anatomy of a successful in-house enterprise high-throughput screening and profiling data analysis system. SLAS Discov. 23, 474–488 (2018).
pubmed: 29370716
doi: 10.1177/2472555217752140
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
pubmed: 25075903
pmcid: 4486245
doi: 10.1038/nmeth.3047
Ting, L., Rad, R., Gygi, S. P. & Haas, W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods 8, 937–940 (2011).
pubmed: 21963607
pmcid: 3205343
doi: 10.1038/nmeth.1714
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Shirley, M. D., Radhakrishna, V. K., Golji, J. & Korn, J. M. PISCES: a package for rapid quantitation and quality control of large scale mRNA-seq datasets. Preprint at bioRxiv https://doi.org/10.1101/2020.12.01.390575 (2020).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https://doi.org/10.1101/060012 (2021).
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) Hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021
pmcid: 4707969
doi: 10.1016/j.cels.2015.12.004
Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325 (2015).
pubmed: 26479923
doi: 10.1038/nm.3954